Nerve Growth Factor (NGF) Study (GCO #09-0367)
Mount Sinai researchers will be participating in a phase 2 clinical trial that is being conducted nationwide. This study will evaluate whether a type of gene therapy technique is safe, well-tolerated, and of benefit to people with Alzheimer’s Disease (AD). In this clinical trial, a study drug named CERE-110 will be injected into an area of the brain affected by AD so that the body can make nerve growth factor (NGF). NGF is a naturally occurring protein that may increase the survival of neurons that die in AD. In this study, half of the participants will receive CERE-110 via neurosurgery and the other half will receive a placebo procedure. Participation will also include a medical examination and cognitive testing. All participants will be carefully monitored by a team of physicians for two years. In addition, all participants will be asked if they want to participate in a separate, open-ended protocol for further clinical observation. This study is open to eligible individuals with mild AD between the ages 55 and 80, who are in good general health, and are able to undergo surgery. If you would like information about this study, please contact Priyanka Ghosh at 212-659-8885 ormailto:email@example.com.